ITUS Corporation is a Nasdaq listed company (Nasdaq: ITUS) that is using the power of the immune system to diagnose cancer. Cchek, its early cancer detection platform, measures subtle changes which occur in the immune system at early tumor formation, and has been validated to work with 15 cancer types including Lung, Breast, Colon, Prostate, Ovarian, Pancreatic, Thyroid, and others. Sensitivity and specificity for the data from ITUS's ongoing patient study is well above existing diagnostic testing, and Cchek is well positioned to compete with new liquid biopsy technologies current under development. The company is currently engaged in a Rights Offering where all shareholders of record as of March 1, 2017 receive the right to purchase additional ITUS common shares at a substantial discount. Please visit www.ITUScorp.com for more information.